VDA-1102 ointment is being developed under an IND from the FDA as a topical treatment for a variety of skin cancers.
It has completed a randomized, double-blinded, placebo-controlled, dose-escalation Phase 1 study in healthy older-adult volunteers which revealed no safety concerns in.
A multi-center randomized, double-blinded, placebo-controlled Phase 2a Proof-of-Concept study in subjects with actinic keratosis (AK) treated once-daily for 28 days was completed. This study established that VDA-1102 ointment is safe, non-irritating and effective in reducing the number of AK lesions in treatment field (for topline data from this study see press release).
A Phase 2b dose ranging study in subjects with actinic keratosis (AK) is ongoing (NCT03538951).